ClinicalTrials.gg
CompletedNCT03996694Updated Feb 5, 2021Results posted

Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.

A Phase 1 interventional study of Belbuca 300 µg and Belbuca 600 µg in Respiratory Depression, sponsored by BioDelivery Sciences International. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-05.

Sponsored by BioDelivery Sciences International · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 349 studies in Respiratory Insufficiency with a site in United States — 44 open to participants now, 60 under way, 1 of them phase 3. Respiratory Insufficiency · United States.

Enrollment
182nd of 253
19 · median 42
Started
2019
with 16 others
Phase 1
23 of 349
none open now
Registered
203rd of 349
by date

Among the 349 studies in Respiratory Insufficiency with a site in United States, this one is the 182nd largest by enrollment of the 253 interventional ones that give a count, is one of 17 that started in 2019, is one of 23 in phase 1, and was the 203rd registered.

Respiratory Insufficiency

1,370 studies on the registry are indexed under Respiratory Insufficiency; 264 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

44 of the 349 studies in Respiratory Insufficiency with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Respiratory Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to explore and compare VRH after administration of Belbuca, Oxycodone HCl and Placebo in recreational opioid users. This is a single-center, double -blind, double-dummy , placebo-controlled randomized crossover study in up to 18 men and women self identifying as recreational users. This study will consist of a screening phase, treatment phase (which includes the Naloxone Challenge test) and follow-up visit.

03

Conditions studied

  • Respiratory Depression

Keywords

  • Chronic Pain
  • Ventilatory Response to Hypercapnia (VRH)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects 18 to 55 years of age, inclusive.
  2. Subjects are in good health as indicated by medical history, PE, vital signs, oxygen saturation, clinical laboratory tests, and 12-lead . A status of good health will be defined by the absence of evidence of any , active or chronic disease based on these assessments, in the opinion of the investigator.
  3. Subjects with a (BMI) of 18.0 to 33.0 kg/m2, inclusive, and body weight greater than 50 kg, inclusive.
  4. Subject is able to speak, read, and understand English and voluntarily provide written to participate in the study.
  5. Subjects have healthy oral mucosa as determined by examination at screening and admission to the clinical facility.
  6. Subject must be a recreational opioid user who is not currently dependent on opioids (based on self-reported criteria and a Clinical Opiate Withdrawal Scale [COWS] score ≤5 on the Naloxone Challenge) but has experience in the use of opioids for non-therapeutic purposes (ie, for psychoactive effects) on at least 10 occasions within the last year and at least once in the 12 weeks prior to the screening visit.
  7. Subject demonstrates adequate VRH at screening during VRH assessment, defined as a minimum increase in ETCO2 of 10 mmHg and an increase in minute ventilation appropriate per investigator's discretion.
  8. Ability and willingness to abstain from alcohol-, caffeine-, and xanthine-containing beverages or food (eg, coffee, tea, cola, chocolate, energy drinks) as well as poppy seeds from 48 hours (2 days) prior to each admission to the clinical facility until study discharge (including clinic furloughs).
  9. Female subjects who are non-pregnant, non-lactating, and either for at least 1 year or surgically sterile for at least 3 months, or, if of , will agree to use adequate from 28 days and/or their last confirmed menstrual period prior to study enrollment (whichever is longer) until 90 days after the follow-up visit. Male subjects, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from first admission to the clinical research center until 90 days after the follow-up visit. Adequate contraception (for both males and females) is defined as using spermicide with a single barrier method: diaphragm, cervical cap, or condom. For female participants and female partners of male participants, being surgically sterilized or using hormonal contraception or an intrauterine device is also acceptable. Also, total abstinence, in accordance with the lifestyle of the subject, is acceptable.
  10. For female subjects: a negative pregnancy test at screening and Day -1 of each treatment period.
  11. Postmenopausal females: defined as 12 months with no menses prior to screening and a serum follicle stimulating hormone (FSH) >40 IU/L at screening.
  12. All prescribed medications, over-the-counter (OTC) medications, dietary supplements or herbal supplements (eg, St. John's Wort extract) must have been stopped at least 14 days prior to the first admission to the clinical research center. An exception is made for acetaminophen, which is allowed up to admission to the clinical research center. An exception is also made for hormonal contraceptives, which may be used throughout the study. Antiemetics may be allowed after the 4-hour VRH assessments while confined in the clinical research unit.

Exclusion criteria

Exclusion Criteria:

  1. Employee of PRA or the Sponsor.
  2. Women who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 90 days after the follow-up visit.
  3. Male subjects with female partners who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 90 days after the follow-up visit.
  4. Has received study medication in another clinical trial within 30 days prior to the first dose of study medication.
  5. Having any disease that, in the opinion of the investigator, poses an unacceptable risk to the subjects.
  6. History of drug allergy diagnosed by a physician. Confirmatory circumstances would include treatment with epinephrine or an Emergency Department.
  7. Subjects who have smoked on a daily basis within 30 days prior to the first dose of study medication. Occasional nicotine use in the form of cigarettes, cigars, or vape pen is allowable (defined as less than half a pack of cigarettes [10 cigarettes], equivalent vaping [100 puffs], or no more than 2 cigars per week). Nicotine replacement therapies (ie, patches and/or gum) may be used without restriction.
  8. Routine or chronic use of more than 3 grams of acetaminophen daily.
  9. Strenuous activity and contact sports within 48 hours (2 days) prior to first admission to the clinical facility and for the duration of the study.
  10. History of donation of more than 450 mL of blood within 60 days prior to dosing in the clinical research center or planned donation before 30 days has elapsed since intake of study drug.
  11. Plasma or donation within 7 days of first dose administration and throughout the entire study.
  12. History of or presence of alcohol dependence. This includes subjects who have never been to a drug rehabilitation program. Alcohol consumption will be prohibited 48 hours prior to admission to the clinical facility and throughout the entire study until discharge.
  13. Positive screening test for surface antigen (HBsAg), anti- virus (HCV) antibodies, or antihuman immunodeficiency virus ()-1 and -2 antibodies.
  14. History or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease, or any other condition, which, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results.
  15. Has any condition in which an opioid is (eg, significant respiratory depression, acute or severe bronchial asthma or hypercarbia, or has or is suspected of having paralytic ileus).
  16. Have a history of or any other lung disease (eg, asthma, bronchitis, obstructive sleep apnea, exercise-induced asthma) that would cause CO2 retention.
  17. Has participated in (within the last 5 years), is currently participating in, or is seeking treatment for substance-related disorders (excluding nicotine and caffeine).
  18. A positive result for drugs of abuse (amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, and opioids, including oxycodone) at screening is acceptable as long as the urine drug screen is negative for these drugs at admission to the clinical facility. A positive test for THC is not exclusionary at screening or at admission to the clinical facility. If a subject has a positive urine drug screen (except THC) upon admission to the clinic (V3-V7) the subject will be dismissed from the clinic and will be allowed to return at a later date (+14 days) to participate in the missed treatment period. A subject may only test positive once (except THC) and be allowed to return.
  19. Has oral sores, mucositis, or inflammation in oral cavity at screening and check-in.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Treatment A: Belbuca 300 µg and oral placebo

    Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.

    Drug: Belbuca 300 µg

  • Experimental
    Treatment B: Belbuca 600 µg and oral placebo

    Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.

    Drug: Belbuca 600 µg

  • Experimental
    Treatment C: Belbuca 900 µg and oral placebo

    Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.

    Drug: Belbuca 900 µg

  • Active comparator
    Treatment D: Oxycodone 30 mg and buccal placebo

    Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.

    Drug: Oxycodone 30 mg

  • Active comparator
    Treatment E: Oxycodone 60 mg and buccal placebo

    Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.

    Drug: Oxycodone 60 mg

  • Placebo comparator
    Treatment F: Oral Placebo and buccal placebo

    Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Respiratory Drive

    Respiratory drive was evaluated by measuring the Ventilatory Response to Hypercapnia (VRH) through assessment of the maximum decrease (Emax) in minute ventilation (mL/min) after administration of Belbuca, Oxycodone hydrochloride, and placebo.

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3 and 4 hours

Secondary outcomes

  1. Pupil Diameter

    Pupil diameter will be assessed by pupillometry predose and at multiple timepoints after completion of Belbuca, oxycodone hydrochloride, and placebo dosing.

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3 and 4 hours

  2. Change in Ratio of Minute Ventilation

    Change in ratio of maximum decrease (Emax) in minute ventilation (mL/min) over maximum (Emax) end-tidal carbon dioxide (CO2, mmHg) after administration of Belbuca, oxycodone hydrochloride, and placebo.

    Time frame: pre-dose, 0.5, 1, 2, 2.5, 3 and 4 hours

  3. Adverse Event (AE) Reporting of Belbuca, Oxycodone Hydrochloride and Placebo for 6 Periods.

    Number of Participants with indicated Adverse Event (AE) in subjects receiving Belbuca, oxycodone hydrochloride, and placebo for 6 periods.

    Time frame: 44 days

07

Results

Posted Feb 5, 2021

Participant flow

First Intervention (1 Day)
Participant flow — First Intervention (1 Day)
MilestoneABCDEFBCDEFACDEFABDEFABCEFABCDFABCDE
Started334333
Completed334333
Not completed000000
First Washout (7 Days)
Participant flow — First Washout (7 Days)
MilestoneABCDEFBCDEFACDEFABDEFABCEFABCDFABCDE
Started334333
Completed322333
Not completed012000
Withdrew: Positive urine drug screen001000
Withdrew: Adverse event010000
Withdrew: Lost to follow-up001000
Second Intervention (1 Day)
Participant flow — Second Intervention (1 Day)
MilestoneABCDEFBCDEFACDEFABDEFABCEFABCDFABCDE
Started322333
Completed322333
Not completed000000
Second Washout (7 Days)
Participant flow — Second Washout (7 Days)
MilestoneABCDEFBCDEFACDEFABDEFABCEFABCDFABCDE
Started322333
Completed322333
Not completed000000
Third Intervention (1 Day)
Participant flow — Third Intervention (1 Day)
MilestoneABCDEFBCDEFACDEFABDEFABCEFABCDFABCDE
Started322333
Completed322333
Not completed000000
Third Washout (7 Days)
Participant flow — Third Washout (7 Days)
MilestoneABCDEFBCDEFACDEFABDEFABCEFABCDFABCDE
Started322333
Completed322323
Not completed000010
Withdrew: Withdrawal by subject000010
Fourth Intervention (1 Day)
Participant flow — Fourth Intervention (1 Day)
MilestoneABCDEFBCDEFACDEFABDEFABCEFABCDFABCDE
Started322323
Completed322323
Not completed000000
Fourth Washout (7 Days)
Participant flow — Fourth Washout (7 Days)
MilestoneABCDEFBCDEFACDEFABDEFABCEFABCDFABCDE
Started322323
Completed322323
Not completed000000
Fifth Intervention (1 Day)
Participant flow — Fifth Intervention (1 Day)
MilestoneABCDEFBCDEFACDEFABDEFABCEFABCDFABCDE
Started322323
Completed322323
Not completed000000
Fifth Washout (7 Days)
Participant flow — Fifth Washout (7 Days)
MilestoneABCDEFBCDEFACDEFABDEFABCEFABCDFABCDE
Started322323
Completed322323
Not completed000000
Sixth Intervention (1 Day)
Participant flow — Sixth Intervention (1 Day)
MilestoneABCDEFBCDEFACDEFABDEFABCEFABCDFABCDE
Started322323
Completed322323
Not completed000000

Outcome measures

PrimaryRespiratory Drive

Respiratory drive was evaluated by measuring the Ventilatory Response to Hypercapnia (VRH) through assessment of the maximum decrease (Emax) in minute ventilation (mL/min) after administration of Belbuca, Oxycodone hydrochloride, and placebo.

Time frame:
pre-dose, 0.5, 1, 1.5, 2, 2.5, 3 and 4 hours
Reported as:
Mean · mL/min
Respiratory Drive
mL/minTreatment A: Belbuca 300 µg and Oral PlaceboTreatment B: Belbuca 600 µg and Oral PlaceboTreatment C: Belbuca 900 µg and Oral PlaceboTreatment D: Oxycodone 30 mg and Buccal PlaceboTreatment E: Oxycodone 60 mg and Buccal PlaceboTreatment F: Oral Placebo and Buccal Placebo
Respiratory Drive23957.34 ± 5554.06122460.95 ± 8957.06423626.79 ± 5025.76721577.15 ± 806.55217223.80 ± 4486.55722645.74 ± 6965.108
SecondaryPupil Diameter

Pupil diameter will be assessed by pupillometry predose and at multiple timepoints after completion of Belbuca, oxycodone hydrochloride, and placebo dosing.

Time frame:
pre-dose, 0.5, 1, 1.5, 2, 2.5, 3 and 4 hours
Reported as:
Mean · mm
Pupil Diameter
mmTreatment A: Belbuca 300 µg and Oral PlaceboTreatment B: Belbuca 600 µg and Oral PlaceboTreatment C: Belbuca 900 µg and Oral PlaceboTreatment D: Oxycodone 30 mg and Buccal PlaceboTreatment E: Oxycodone 60 mg and Buccal PlaceboTreatment F: Oral Placebo and Buccal Placebo
Predose4.93 ± 0.6765.11 ± 1.0634.91 ± 0.5645.11 ± 0.9224.82 ± 0.9624.87 ± 1.150
0.5 hours Post4.65 ± 0.7705.00 ± 1.0204.91 ± 0.6674.17 ± 1.0413.48 ± 1.1474.90 ± 1.041
1 hour Post4.49 ± 0.7744.83 ± 0.9734.32 ± 0.6173.09 ± 0.7412.77 ± 0.7264.71 ± 1.091
1.5 hours Post4.42 ± 0.8334.45 ± 0.8383.85 ± 0.4123.16 ± 0.6932.81 ± 0.7984.75 ± 1.127
2 hours Post3.89 ± 0.7033.80 ± 0.6983.27 ± 0.4763.17 ± 0.7212.7 ± 0.6334.65 ± 0.952
2.5 hours Post3.87 ± 0.7363.56 ± 0.6763.15 ± 0.5173.31 ± 0.6882.87 ± 0.7284.89 ± 1.033
3 hours Post3.67 ± 0.7323.31 ± 0.6882.99 ± 0.5483.28 ± 0.7222.82 ± 0.6654.80 ± 0.963
4 hours Post3.57 ± 0.7203.25 ± 0.6252.92 ± 0.6533.51 ± 0.7162.90 ± 0.6344.89 ± 0.903
SecondaryChange in Ratio of Minute Ventilation

Change in ratio of maximum decrease (Emax) in minute ventilation (mL/min) over maximum (Emax) end-tidal carbon dioxide (CO2, mmHg) after administration of Belbuca, oxycodone hydrochloride, and placebo.

Time frame:
pre-dose, 0.5, 1, 2, 2.5, 3 and 4 hours
Reported as:
Mean · ratio
Change in Ratio of Minute Ventilation
ratioTreatment A: Belbuca 300 µg and Oral PlaceboTreatment B: Belbuca 600 µg and Oral PlaceboTreatment C: Belbuca 900 µg and Oral PlaceboTreatment D: Oxycodone 30 mg and Buccal PlaceboTreatment E: Oxycodone 60 mg and Buccal PlaceboTreatment F: Oral Placebo and Buccal Placebo
Change in Ratio of Minute Ventilation591.74 ± 135.568536.28 ± 195.123576.76 ± 115.782518.81 ± 162.565411.88 ± 100.259546.09 ± 179.371
SecondaryAdverse Event (AE) Reporting of Belbuca, Oxycodone Hydrochloride and Placebo for 6 Periods.

Number of Participants with indicated Adverse Event (AE) in subjects receiving Belbuca, oxycodone hydrochloride, and placebo for 6 periods.

Time frame:
44 days
Reported as:
Number · participants
Adverse Event (AE) Reporting of Belbuca, Oxycodone Hydrochloride and Placebo for 6 Periods.
participantsTreatment A: Belbuca 300 µg and Oral PlaceboTreatment B: Belbuca 600 µg and Oral PlaceboTreatment C: Belbuca 900 µg and Oral PlaceboTreatment D: Oxycodone 30 mg and Buccal PlaceboTreatment E: Oxycodone 60 mg and Buccal PlaceboTreatment F: Oral Placebo and Buccal Placebo
Mild711108122
Moderate112120
Severe000000

Adverse events

Collected over 44 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Belbuca 300 µg and Oral Placebo0/16 (0%)0/16 (0%)8/16 (50%)
Treatment B: Belbuca 600 µg and Oral Placebo0/16 (0%)0/16 (0%)12/16 (75%)
Treatment C: Belbuca 900 µg and Oral Placebo0/17 (0%)0/17 (0%)12/17 (70.6%)
Treatment D: Oxycodone 30 mg and Buccal Placebo0/15 (0%)0/15 (0%)9/15 (60%)
Treatment E: Oxycodone 60 mg and Buccal Placebo0/16 (0%)0/16 (0%)14/16 (87.5%)
Treatment F: Oral Placebo and Buccal Placebo0/16 (0%)0/16 (0%)2/16 (12.5%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventTreatment A: Belbuca 300 µg and Oral PlaceboTreatment B: Belbuca 600 µg and Oral PlaceboTreatment C: Belbuca 900 µg and Oral PlaceboTreatment D: Oxycodone 30 mg and Buccal PlaceboTreatment E: Oxycodone 60 mg and Buccal PlaceboTreatment F: Oral Placebo and Buccal Placebo
PruritusSkin and subcutaneous tissue disorders0/161/164/174/159/160/16
SomnolenceNervous system disorders0/164/164/173/157/161/16
VomitingGastrointestinal disorders1/161/164/172/156/160/16
NauseaGastrointestinal disorders0/164/164/172/155/160/16
Euphoric MoodPsychiatric disorders3/163/164/174/154/160/16
DizzinessNervous system disorders1/164/162/171/152/160/16
HeadacheNervous system disorders2/161/161/170/151/160/16
HyperhidrosisSkin and subcutaneous tissue disorders1/161/160/170/152/161/16
Dry MouthGastrointestinal disorders0/160/161/171/151/160/16
Feeling hotGeneral disorders0/160/160/171/151/160/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Arms
Mean33.1 ± 4.52
Sex: Female, Male
Sex: Female, Male(Participants)All Arms
Female1
Male18
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Arms
American Indian or Alaska Native3
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White14
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • PRA-EDS
    Salt Lake City, Utah 84124, United States
09

References and documents

Publications

  • Webster LR, Cater J, Smith T. Pharmacokinetics of Buprenorphine Buccal Film and Orally-administered Oxycodone in a Respiratory Study: An Analysis of Secondary Outcomes from a Randomized Controlled Trial. Pain Ther. 2022 Sep;11(3):817-825. doi: 10.1007/s40122-022-00380-2. Epub 2022 May 7. PubMed 35524938 ↗
  • Webster LR, Hansen E, Cater J, Smith T. A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory Drive. Adv Ther. 2020 Nov;37(11):4685-4696. doi: 10.1007/s12325-020-01481-0. Epub 2020 Sep 25. PubMed 32978722 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Oct 2019, 3 months.

Results were first posted in Feb 2021, 1 year 3 months after primary completion.

Of 12 phase 1 interventional studies under Respiratory Insufficiency, half reached primary completion within 11 months of starting (the median); a quarter within 3 and three quarters within 16. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2019
First posted
Jun 25, 2019
StartActual
Jul 23, 2019
Primary completionActual
Oct 27, 2019
CompletionActual
Oct 27, 2019
Results first posted
Feb 5, 2021
Last update
Feb 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03996694
Lead sponsor
BioDelivery Sciences International
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Jun 25, 2019
Start date
Jul 23, 2019
Primary completion
Oct 27, 2019
Completion
Oct 27, 2019
Results posted
Feb 5, 2021
Last update
Feb 5, 2021

Study contacts

Lynn Webster
principal investigator · PRA Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Buprenorphine · Oxycodone

Start the discussion